Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11
Needham has reiterated its Buy rating for Nkarta (NKTX.US), maintaining a target price of $11. This indicates the firm's continued confidence in the company's prospects.
Nkarta at H.C. Wainwright cell therapy conference: autoimmune push By Investing.com
Nkarta (NKTX) presented its allogeneic CAR NK platform for autoimmune diseases at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. The company is focusing on B-cell-driven autoimmune diseases like lupus nephritis and rheumatoid arthritis, aiming for outpatient treatment and off-the-shelf manufacturing. A key data readout is expected in 2026, which will cover efficacy, dosing, and potential FDA guidance for their NKX019 program.
Price to sales forward of Nkarta, Inc. – NASDAQ:NKTX
This page displays the forward "Price to sales" metric for Nkarta, Inc. (NASDAQ: NKTX). The content is primarily a data placeholder, indicating the period, value, and change for this financial metric, but the actual numerical data is not provided in the extracted content.
Price to book forward of Nkarta, Inc. – NASDAQ:NKTX
The article "Price to book forward of Nkarta, Inc. – NASDAQ:NKTX" provides a snapshot of Nkarta, Inc.'s stock (NKTX) on the Nasdaq. It shows the company's financial data, specifically focusing on its price to book forward metric. The brief content indicates that the market was closed at the time, with no trades occurring.
Enterprise value to revenue forward of Nkarta, Inc. – NASDAQ:NKTX
This article provides financial information for Nkarta, Inc. (NASDAQ: NKTX), specifically focusing on its enterprise value to revenue forward. It appears to be a financial data page from TradingView, offering an overview of the company's financials, news, and other related market data.
Nkarta sets June 30 fireside chat on CAR-NK autoimmune therapy
Nkarta (Nasdaq: NKTX), a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will host a fireside chat at 2 p.m. ET to discuss the company’s investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases. A webcast and replay will be available for approximately 90 days on Nkarta's investor website.
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Nkarta, Inc. announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference, where President Nadir Mahmood will share updates on the company's investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases. The fireside chat is scheduled for Tuesday, June 30th, at 2 p.m. ET, and will be webcast live with a replay available afterward. Nkarta is advancing allogeneic, off-the-shelf natural killer cell therapies for autoimmune diseases.
TD Cowen Initiates Nkarta(NKTX.US) With Buy Rating
TD Cowen has initiated coverage on Nkarta (NKTX.US) with a Buy rating. The firm has set a price target of $10.00 for the biopharmaceutical company.
TD Cowen initiates Nkarta stock with buy rating on NK cell therapy
TD Cowen has initiated coverage on Nkarta Inc. (NASDAQ:NKTX) with a "buy" rating, citing the potential of its lead candidate NKX019, an engineered natural killer cell therapy, to advance the standard of care in autoimmune diseases. The stock has seen a 60% surge over the past year, and analysts have set price targets suggesting significant upside. Recent FDA approvals for protocol changes in Nkarta's clinical trials are expected to streamline patient monitoring and administration, while other analysts like Mizuho and Stifel have adjusted price targets but maintained positive ratings.
Shares of Nkarta (NKTX) CEO Paul J. Hastings decrease by 1,776. He still owns 390,247 shares.
Nkarta, Inc. CEO Paul J. Hastings reported a sale of 1,776 common stock shares at $2.71 each, primarily to cover tax withholding obligations related to Restricted Stock Unit vesting. This transaction is considered routine and non-discretionary, as indicated in the filing. Following the sale, Hastings retains a direct holding of 390,247 shares, including 2,000 shares acquired through an Employee Stock Purchase Plan.
Nkarta (NKTX) Stock Price, News & Analysis
Nkarta, Inc. (NASDAQ: NKTX) is a clinical-stage biotechnology company developing off-the-shelf natural killer (NK) cell therapies for cancer. The stock currently trades at $2.79, with analysts giving it a "Moderate Buy" consensus rating and a price target of $10.75, representing significant upside potential. Despite positive earnings growth projections, the company has negative P/E ratios and a low P/B ratio, indicating potential undervaluation relative to assets.
Nkarta Inc (NKTX) Institutional Confidence
Nkarta Inc (NKTX) has an institutional shareholding score of 7.00, placing it 81st out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 82.11%, which is a 4.32% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 2.43% of outstanding shares.
Nkarta Inc (NKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Nkarta Inc (NKTX), highlighting its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. The stock is currently ranked 144 out of 389 in the Biotechnology & Medical Research industry for price momentum, suggesting suitability for range-bound swing trading between $2.34 and $3.36. Based on a combination of technical indicators and moving averages, the overall signal for Nkarta Inc is currently a "Buy."
Nkarta Inc (NKTX) Valuation: PE, PB & Fair Value Analysis
Nkarta Inc (NKTX) currently has a valuation score of 8.53, placing it 115th out of 389 companies in the Biotechnology & Medical Research industry. The company's current P/E ratio is -2.12, which is significantly below its recent high and above its recent low. However, relevant data for P/B, P/S, and P/CF ratios have not been disclosed by the company yet.
Nkarta Inc (NKTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a brief overview of Nkarta Inc.'s (NKTX) revenue breakdown. It states that relevant data for business segments and regional revenue and profit contribution for fiscal years 2018, 2019, and 2020 have not yet been disclosed by the company. The only specific data point mentioned is 0.00 for United States revenue proportion.
Nkarta Inc (NKTX) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of Nkarta Inc's (NKTX) financial health, ranking it 355 out of 388 in the Biotechnology & Medical Research industry with a weak financial status and low operating efficiency. The report details the company's scores across various financial dimensions such as Financials, Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns. Key financial data for certain metrics are noted as not yet disclosed by the company.
Nkarta Inc (NKTX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Nkarta Inc (NKTX), listing its major shareholders and their respective proportions as of recent updates. It breaks down shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in shares held by key entities. Additionally, it highlights related ETFs that include Nkarta Inc.
Nkarta Inc (NKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article from TradingKey provides a dividend and stock split history for Nkarta Inc (NKTX). It indicates that Nkarta Inc has not distributed any dividends over the past five years and shows no record of stock splits. The report emphasizes the absence of both dividend and stock split data for the company.
Nkarta Inc (NKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Nkarta Inc (NKTX) has an earnings forecast score of 9.00, placing it 14th out of 388 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $11.00 for NKTX, with a "Strong Buy" rating from 4 analysts, indicating a significant upside potential of +348.47%. The company's previous quarter's EPS matched market expectations at -$0.37, and the next quarter's EPS is projected to be -$0.39.
Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay
Nkarta (NKTX) shareholders recently re-elected directors Ali Behbahani and Zachary Scheiner, ratified Ernst & Young LLP as their independent auditor, and approved executive compensation. They also expressed a preference for annual say-on-pay votes, which the board has adopted. TipRanks' AI Analyst Spark rates NKTX as Neutral, citing weak financial performance offset by a conservative balance sheet and positive technical momentum, with a recent analyst rating a Buy with a $9.00 price target.
Nkarta (NASDAQ: NKTX) reports 37,000-share option grant tied to RA Capital
Nkarta, Inc. (NASDAQ: NKTX) has reported a Form 4 detailing a compensation-related stock option grant of 37,000 shares of common stock at an exercise price of $2.46. This grant is tied to RA Capital-affiliated entities, with Dr. Scheiner holding the option for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund LP. The option vests 100% on June 10, 2027, or the day before the first annual stockholder meeting after the grant, with accelerated vesting under certain conditions like a change in control, death, or disability.
Nkarta (NKTX) investors approve directors, auditor and annual say-on-pay
Nkarta, Inc. held its 2026 annual meeting where shareholders elected two Class III directors, Ali Behbahani and Zachary Scheiner, and ratified Ernst & Young LLP as the independent auditor for the year ending December 31, 2026. Stockholders also approved, on an advisory basis, the compensation paid to the named executive officers and decided that future advisory executive compensation votes will be held annually. The voting results for all proposals, including director elections, auditor ratification, and executive compensation, were detailed in an 8-K filing.
Nkarta (NKTX) director receives stock options on 37,000 common shares
Nkarta, Inc. director George Vratsanos was granted stock options for 37,000 shares of common stock at an exercise price of $2.46 per share. This compensation-related award vests 100% on the earlier of June 10, 2027, or the day before the first annual stockholder meeting following the grant, with accelerated vesting under certain conditions like a change in control or Vratsanos's separation due to death or disability. The options are set to expire on June 9, 2036.
Nkarta (NKTX) director George Simeon awarded 37,000-share stock option grant
Nkarta, Inc. director George Simeon was granted a stock option for 37,000 shares of common stock with an exercise price of $2.4600 per share, expiring on June 9, 2036. The option vests 100% on the earlier of June 10, 2027, or the day before the first annual stockholders' meeting after the grant date, with accelerated vesting conditions for change in control, death, or disability. This transaction was reported in a Form 4 SEC filing.
Nkarta (NKTX) director awarded 37,000 stock options vesting in 2027
Nkarta, Inc. director Ali Behbahani has been granted 37,000 stock options with an exercise price of $2.46 per share and an expiration date of June 9, 2036. These options are set to fully vest on the earlier of June 10, 2027, or the day before the first annual stockholder meeting post-grant. Accelerated vesting provisions apply in cases of a change in control, or Behbahani's death or disability.
NKTX - Nkarta Inc Stock Price and Quote
This article provides comprehensive financial data and news for Nkarta Inc (NKTX), a biopharmaceutical company focused on natural killer cell therapies. It details stock performance, key financial metrics, insider transactions, and a history of analyst ratings. Recent news highlights include clinical trial updates for autoimmune diseases and cancer, participation in investor conferences, and quarterly financial results.
Nkarta’s NK Cell Therapy Push Moves Into Outpatient Care
Nkarta, a clinical-stage biotech developing allogeneic NK cell therapies, has received FDA agreement for outpatient dosing in its NKX019 autoimmune trials, aiming to broaden access and lower treatment burden. The company's stock (NKTX) has significantly outperformed the broad market over the last year, driven by progress in its NKX019 program and improved sentiment around CAR-NK approaches. While high-risk due to its pre-revenue stage, initial clinical data is expected in 2026, which will be a major catalyst for its valuation.
NEA (NKTX) drops below 5% ownership in latest Schedule 13D/A filing
New Enterprise Associates (NEA) and its affiliated entities have filed an Amendment No. 3 to their Schedule 13D for Nkarta, Inc. (NKTX), indicating their beneficial ownership has fallen to 4.9% of outstanding shares. This change is primarily due to an increase in Nkarta's total shares outstanding rather than recent transactions by NEA. The filing clarifies that NEA holds its stake for investment purposes and has no current plans for corporate actions or changes to Nkarta's management.
Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m
Nkarta's market capitalization has dropped to US$201m. Insiders, particularly CEO Paul Hastings, sold US$69k worth of stock at an average price of US$2.06 per share over the past year, before the recent 11% stock price drop. The article notes low insider ownership and a lack of recent insider buying, which it considers unenthusiastic signals for the company.
Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m
Insiders at Nkarta, Inc. sold US$69k worth of stock over the past year at an average price of US$2.06, with the largest sale made by CEO Paul Hastings below the current stock price. The company's market cap recently fell by US$24m (11%), but insiders avoided these losses due to their earlier sales. The article notes the low insider ownership (US$820k) and absence of recent insider buying as potentially discouraging signals for investors.
Nkarta, Inc. Stock 12‑Month Price Target Raised to $11.8, Implies 260% Upside
The average 12-month price target for Nkarta, Inc. (NKTX) stock has been raised from $11.6 to $11.8 by 5 analysts, with individual forecasts ranging from $9 to $16 per share. This new target suggests a potential upside of approximately 260% from the May 12 closing price. The consensus rating for Nkarta, Inc. remains a "Buy" from all 5 covering analysts.
Nkarta Price Target Maintained With a $11.00/Share by Needham
Needham has maintained its price target for Nkarta (NKTX) at $11.00 per share. This financial update follows the company's third-quarter report, suggesting ongoing analyst confidence in the stock's valuation. The article also briefly mentioned Unity Software's fourth-quarter financial results.
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Nkarta, Inc. reported its first-quarter 2026 financial results, highlighting ongoing enrollment in its NKX019 clinical trials (Ntrust-1 and Ntrust-2) for autoimmune diseases. The company announced regulatory agreement for expanding NKX019 into community-based, outpatient settings and expects initial clinical data from these trials to be presented at a medical meeting later in 2026. Nkarta's cash balance of $266.7 million as of March 31, 2026, is projected to fund operations into 2029.
Nkarta (NKTX) Q1 2026 results: NKX019 trial progress and cash runway into 2029
Nkarta (NKTX) reported its Q1 2026 financial results, showing a narrower net loss of $27.8 million and extending its cash runway into 2029 with $266.7 million in cash and equivalents. The company also provided clinical updates on its NKX019 autoimmune program, including FDA agreement for outpatient dosing and expansion to include rheumatoid arthritis in its Ntrust-2 trial, with initial clinical data expected in 2026. These advancements aim to broaden patient access and accelerate trial progress for its CAR-NK cell therapy.
FDA deal lets Nkarta test autoimmune cell therapy in community clinics
Nkarta (Nasdaq: NKTX) reported Q1 2026 financial results, including a net loss of $27.8 million but maintaining a cash balance of $266.7 million, expected to fund operations into 2029. The company announced a significant FDA agreement allowing outpatient dosing and re-dosing of its NKX019 cell therapy in community settings, and the expansion of its Ntrust-2 study to include rheumatoid arthritis patients. Initial clinical data from the Ntrust-1 and Ntrust-2 trials are anticipated to be presented at a medical meeting in 2026.
Nkarta Inc NKTX
This page provides real-time market data for Nkarta Inc (NKTX), including its current stock price, recent performance, and market capitalization. It also offers sections for financials, discussions, and analysis, along with general tools for investment research provided by TradingKey. The platform emphasizes risk warnings regarding investment products and third-party analysis.
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Hold" by Analysts
Analysts have issued an average "Hold" rating for Nkarta, Inc. (NASDAQ:NKTX), with a consensus twelve-month price target of $11.33. The clinical-stage biotechnology company recently missed its quarterly EPS estimates, reporting -$0.37 against an expected -$0.32, and shares are currently trading around $2.77. Institutional investors hold approximately 80.54% of the company's stock.
[ARS] Nkarta, Inc. SEC Filing
This article reports on Nkarta, Inc.'s SEC filing identified as ARS, with a low impact and neutral sentiment. The filing occurred on April 23, 2026, at 04:42 PM, and the document is available in PDF format via SEC EDGAR. Nkarta, Inc. (NKTX) is a biotechnology company with a market cap of $236.68 million.
Executive pay, auditor and board elections on ballot at Nkarta (NKTX) 2026 virtual meeting
Nkarta, Inc. will hold a virtual annual meeting on June 10, 2026, where stockholders will vote on several key proposals. These include the election of two Class III directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm, an advisory vote on executive compensation, and the frequency of future say-on-pay votes, with the board recommending an annual frequency. The proxy statement details executive and director compensation, including CEO total compensation of $2,978,038 in 2025, and outlines the company's governance practices.
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
Nkarta, Inc. has reached an agreement with the FDA for key changes to its Ntrust-1 and Ntrust-2 clinical trials for NKX019, an investigational CAR-NK cell therapy for autoimmune diseases. These changes will allow for outpatient dosing, significantly reducing patient burden and expanding access to community rheumatology centers. Additionally, the protocol amendments enable the option to redose patients and will add a rheumatoid arthritis cohort to the Ntrust-2 study.
Stifel Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11
Stifel has reiterated its Buy rating on Nkarta (NKTX.US) and maintained a target price of $11. This indicates a continued positive outlook from the financial firm regarding the company's stock performance.
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11
Needham has reaffirmed its Buy rating for Nkarta (NKTX.US), maintaining a target price of $11. This indicates the firm's continued confidence in the company's prospects. Investors may view this sustained recommendation as a positive signal for Nkarta's stock.
Nkarta targets 2-hour monitoring, not overnight stays, in cell therapy trials
Nkarta has reached an agreement with the FDA to amend protocols for its Ntrust-1 and Ntrust-2 clinical trials, allowing for outpatient dosing of NKX019 and reducing post-dose monitoring from 24 hours to 2 hours. This change aims to reduce patient burden and expand access to community rheumatology centers. The amendments also include an option to re-dose participants and will add a rheumatoid arthritis cohort to Ntrust-2, with initial data expected this year.
Nkarta Announces FDA Agreement on Outpatient Dosing of
Nkarta, Inc. has reached an agreement with the FDA for key changes to its Ntrust-1 and Ntrust-2 clinical trials, allowing outpatient administration of NKX019 and reducing patient burden. This amendment will also enable the addition of a rheumatoid arthritis cohort to the Ntrust-2 study and allow for re-dosing of patients. These changes aim to expand access to community rheumatology centers and optimize treatment responses.
Nkarta Announces FDA Agreement on Outpatient Dosing of
Nkarta, Inc. announced FDA agreement on key changes to its Ntrust-1 and Ntrust-2 clinical trials for NKX019, an investigational CAR-NK cell therapy for autoimmune diseases. These amendments will enable outpatient administration, reducing patient burden and expanding access to community rheumatology centers. The changes also include an option to redose patients and the addition of a rheumatoid arthritis cohort to the Ntrust-2 study, with initial data expected this year.
Nkarta Announces FDA Agreement on Outpatient Dosing of
Nkarta, Inc. has reached an agreement with the FDA for key changes to its Ntrust-1 and Ntrust-2 clinical trials, enabling outpatient administration of NKX019 and reducing patient burden. The amendments also allow for re-dosing patients and will add a rheumatoid arthritis cohort to the Ntrust-2 study, expanding access and optimizing treatment responses. Initial data from these trials is expected to be presented at a medical meeting later this year.
Nkarta to Participate in Needham Virtual Healthcare Conference
Nkarta, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference. CEO Paul Hastings will join a virtual panel discussion on "Cell Therapy in Autoimmune: State of the Art and What Comes Next," and President Nadir Mahmood will provide updates on the company’s investigational CAR-NK cell therapy. A webcast of the fireside chat will be available on Nkarta's investor website.
Nkarta to Participate in Needham Virtual Healthcare Conference
Nkarta, Inc. will participate in the 25th Annual Needham Virtual Healthcare Conference. CEO Paul Hastings will join a virtual panel discussion on cell therapy in autoimmune diseases, while President Nadir Mahmood will lead a fireside chat discussing updates on the company's investigational CAR-NK cell therapy. A webcast of the fireside chat will be available on Nkarta's website.
Nkarta to Participate in Needham Virtual Healthcare Conference
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company focused on engineered natural killer (NK) cell therapies for autoimmune diseases, announced its participation in the 25th Annual Needham Virtual Healthcare Conference. CEO Paul Hastings will join a panel discussion on "Cell Therapy in Autoimmune" on April 15, and later that day, President Nadir Mahmood will discuss the company's investigational CAR-NK cell therapy in a fireside chat. A webcast of the fireside chat will be available on Nkarta's investor relations website.
Nkarta leaders to discuss autoimmune cell therapy at Needham event
Nkarta (Nasdaq: NKTX) announced its participation in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. CEO Paul Hastings will join a panel discussion on cell therapy in autoimmune diseases, and President Nadir Mahmood will deliver a fireside chat providing updates on the company's investigational CAR-NK therapy for B cell-mediated autoimmune diseases. A webcast of the fireside chat will be available on Nkarta's Investors website and archived for approximately 90 days.
